Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human
Fc-fusion proteins
FcRn transgenic mice
Gene editing
IgG
drug disposition
humanized antibodies
humanized mouse model
mAb
monoclonal antibody
neonatal Fc receptor (FcRn)
pharmacokinetics
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
13
8
2021
Statut:
ppublish
Résumé
A major asset of many monoclonal antibody (mAb)-based biologics is their persistence in circulation. The MHC class I family Fc receptor, FCGRT, is primarily responsible for this extended pharmacokinetic behavior. Engagement of FCGRT with the crystallizable fragment (Fc) domain protects IgG from catabolic elimination, thereby extending the persistence and bioavailability of IgG and related Fc-based biologics. There is a need for reliable in vivo models to facilitate the preclinical development of novel IgG-based biologics. FcRn-humanized mice have been widely accepted as translationally relevant surrogates for IgG-based biologics evaluations. Although such FCGRT-humanized mice, especially the mouse strain, B6.Cg-Fcgrt
Identifiants
pubmed: 33025844
doi: 10.1080/19420862.2020.1829334
pmc: PMC7577234
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Histocompatibility Antigens Class I
0
Immunoglobulin Fc Fragments
0
Immunoglobulin gamma-Chains
0
Receptors, Fc
0
Fc receptor, neonatal
TW3XAW0RCY
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
1829334Subventions
Organisme : NIH HHS
ID : R24 OD011190
Pays : United States
Références
Circ Res. 2012 Dec 7;111(12):1494-503
pubmed: 22967807
J Mol Biol. 1992 Mar 20;224(2):487-99
pubmed: 1560463
Gastroenterology. 2009 Nov;137(5):1746-56.e1
pubmed: 19664634
J Immunol. 2007 Sep 1;179(5):2999-3011
pubmed: 17709515
MAbs. 2018 Jul;10(5):751-764
pubmed: 29634430
J Autoimmun. 1989 Dec;2(6):869-75
pubmed: 2619870
MAbs. 2018 Jul;10(5):803-813
pubmed: 29621428
Curr Opin Biotechnol. 2011 Dec;22(6):868-76
pubmed: 21862310
Int Immunol. 2006 Dec;18(12):1759-69
pubmed: 17077181
Curr Opin Biotechnol. 2009 Dec;20(6):692-9
pubmed: 19889530
Clin Ther. 1999 Feb;21(2):309-18
pubmed: 10211534
J Mol Biol. 2005 Feb 4;345(5):1071-81
pubmed: 15644205
J Immunol. 2007 Oct 1;179(7):4580-8
pubmed: 17878355
MAbs. 2011 Sep-Oct;3(5):422-30
pubmed: 22048693
Sci Rep. 2016 Aug 24;6:32154
pubmed: 27555521
Front Immunol. 2019 Jul 10;10:1540
pubmed: 31354709
MAbs. 2017 Jul;9(5):756-766
pubmed: 28463063
J Clin Immunol. 2010 Nov;30(6):790-7
pubmed: 20848168
MAbs. 2016 Aug-Sep;8(6):1064-78
pubmed: 27232760
Nat Rev Immunol. 2007 Sep;7(9):715-25
pubmed: 17703228
J Clin Invest. 1970 Apr;49(4):673-80
pubmed: 5443170
Mamm Genome. 2012 Apr;23(3-4):259-69
pubmed: 22193411
MAbs. 2013 May-Jun;5(3):397-405
pubmed: 23549129
Xenobiotica. 2014 Dec;44(12):1127-34
pubmed: 25030041
MAbs. 2013 Nov-Dec;5(6):860-71
pubmed: 24492342
J Immunol. 2001 Mar 1;166(5):3266-76
pubmed: 11207281
Int Immunol. 2001 Dec;13(12):1551-9
pubmed: 11717196
Nature. 1964 Sep 26;203:1352-4
pubmed: 14207307